

SCIENTIFIC PROGRAM

8:45 am Registration

9:00 am – 9:05 am | Welcome and Introduction of the Meeting, *Paolo A. Ascierto*

9:05 am – 9:20 am | Framing Remarks: Cancer Vaccines 2026, why now? *Bernard A. Fox*

- What has changed since earlier vaccine failures?
- Personalized vs shared antigen strategies
- mRNA/LNP, neoantigen prediction, immune monitoring, and combination immunotherapy
- Defining success: tumor regression, recurrence prevention, durability, or cure

9:20 am – 9:45 am | Dark Proteome – The Undiscovered Targets for Cancer Immunotherapy, *Reuven Agami*

SESSION I: Dark Proteome Cancer Vaccines – Where are they going?

Chairpersons: Paolo A. Ascierto, Bernard A. Fox

09:45 am - 10:05 am | Expanding the landscape of tumor antigens in breast cancer through Immunopeptidomics, *Eralda Kina*

Q&A

10:05 am - 10:25 am | Microproteins as cancer vaccine targets in liver cancer and beyond, *Júlia Perera Bel*

Q&A

10:25 am - 10:45 am | Pancreatic Cancer, *Rishi Surana*

Q&A

10:45 am -11:00 am | Panel Discussion, *Reuven Agami, Paolo A. Ascierto, Bernard A. Fox, Eralda Kina, Júlia Perera Bel, Rishi Surana*

- Shared antigen off-the-shelf vaccine approaches
- Lessons from emerging FIH trials
- What endpoints matter: immune response, pathologic response, recurrence-free survival, overall survival

11:00 am – 11.15 am Coffee Break

SESSION II: The Clinical Landscape – Shared Canonical and Neoantigens

Chairpersons: Paolo A. Ascierto, Bernard A. Fox

11:15 am – 11:35 am | Minimal residual disease vs metastatic disease: focus on Melanoma, *Paolo A. Ascierto*

Q&A

11:35 am - 11:55 am | Fixed vaccines vs personalized vaccines, *Nina Bhardwaj*

Q&A

11:55 am-12:15 pm | Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC), *Craig L Slingluff Jr*

Q&A

ideA-Z Project in progress S.r.l.

Corso G. Matteotti, 48 - 20081 Abbiategrasso MI Tel. 02.9462227 - Fax 02.87152261 - E-mail info@idea-z.it
Codice Fiscale, P. IVA 03373190960, Rea MI-1670871 - Capitale Sociale € 10.000,00 i.v.

Provider E.C.M. Standard n. 335
Azienda con Sistema di Qualità certificato ISO 9001:2015



12:15 pm - 12:35 pm | Primary results from a randomized phase II trial of BNT111 in combination with cemiplimab with calibrator monotherapy arms in anti-PD-(L)1; *Paolo A. Ascierto*

Q&A

12:35 pm – 12:50 pm | Panel Discussion, Paolo A. Ascierto, Bernard A. Fox, Nina Bhardwaj, Craig L Slingluff Jr

Focus: Which antigens should vaccines target? What do the trials say?

- Private neoantigens vs recurrent driver mutations
- Tumor-associated antigens, cancer-testis antigens, viral antigens
- Antigen clonality, heterogeneity, loss, and immune escape
- Antigen spreading as a marker of productive immunity
- Implications for lung, prostate, and melanoma vaccine design

12:50 pm – 1:50 pm Lunch

SESSION III: What Should Be Added to Cancer Vaccines and When? Combination immunotherapy, schedule, sequencing, and immune context

Chairpersons: Paolo A. Ascierto, Bernard A. Fox

01:50 pm – 02:10 pm | PD-1 biology, memory T-cell formation, costimulation, and myeloid biology, *Rom Leidner*

Q&A

02:10 pm – 02:30 pm | Impact of LNP delivered mRNA on the response to anti-PD-1, *Christiano Marconi*

Q&A

02:30 pm – 02:50 pm | AI in trial monitoring and immune-response assessment, *Carlo Bifulco*

Q&A

02:50 pm – 03:00 pm | CME Test

RATIONAL

After decades of research and clinical trials, vaccines are beginning to impact patient outcomes and pushing the boundaries of research in the field of immuno-oncology. While the future is bright, we still have a long way to go.

This year, the third edition of the event will be an international meeting for experts to share and discuss the latest findings and future perspectives on cancer vaccines and immunotherapy.

ACRONIMI:

PD-1 (programmed death-1)

HERV (Human Endogenous Retrovirus)

TLR3 (Toll-like receptor 3)

CD40 (Cluster of Differentiation 40)

LNP (Lipid Nanoparticles)

ideA-Z Project in progress S.r.l.

Corso G. Matteotti, 48 - 20081 Abbiategrasso MI Tel. 02.9462227 - Fax 02.87152261 - E-mail info@idea-z.it
Codice Fiscale, P. IVA 03373190960, Rea MI-1670871 - Capitale Sociale € 10.000,00 i.v.

Provider E.C.M. Standard n. 335
Azienda con Sistema di Qualità certificato ISO 9001:2015

COGNOME	NOME	LAUREA	SPECIALIZZAZIONE	STRUTTURA	AFFILIAZIONE
AGAMI	REUVEN	Biologia	Biologia	The Netherlands Cancer Institute;	Head of Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Full Professor Department of Molecular Genetics, Erasmus MC, Rotterdam, The Netherlands
ASCIERTO	PAOLO A.	Medicina e Chirurgia	Oncologia	National Cancer Institute IRCCS "Fondazione G. Pascale"	Full Professor, University of Naples Federico II; Director of Melanoma, Cancer Immunotherapy and Development Therapeutics Unit
BHARDWAJ	NINA	Medicina e chirurgia	Immunologia; Oncologia	The Tisch Cancer Institute at Mount Sinai	Director of Immunotherapy; Medical Director of the Vaccine and Cell Therapy Laboratory; Ward-Coleman Chair in Cancer Research; Professor of Medicine (Hematology and Medical Oncology) and Urology, The Tisch Cancer Institute at Mount Sinai, New York, US
BIFULCO	CARLO	Medicina e Chirurgia	Anatomia Patologica	Providence Cancer Institute	Medical Director of Cancer Genomics and Precision Oncology, Providence Cancer Institute, Portland, Oregon, US
FOX	BERNARD A.	Medicina e chirurgia	Immunologia	Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Institute	Chief of Laboratory of Molecular and Tumor Immunology
SURANA	RISHI	Medicina e chirurgia	Medicina Interna; Oncologia	Dana-Farber Cancer Institute; Harvard Medical School	Medical Oncologist, Dana-Farber Cancer Institute; Instructor in Medicine, Harvard Medical School, Boston, MA, USA
KINA	ERALDA	Biologia	Biologia	Institute for Research in Immunology and Cancer (IRIC), University of Montreal	Medical Oncologist and Researcher, Charles-Lemoyne Hospital, Institute for Research in Immunology and Cancer (IRIC), University of Montreal, Montreal, Quebec, Canada
LEIDNER	ROM	Medicina e Chirurgia	Oncologia	Earle A. Chiles Research Institute, Providence Cancer Institute	Director Immune Cell Experimental Therapy; Co-Director, Head and Neck Cancer Program Member, Earle A. Chiles Research Institute, Providence Cancer Institute Portland, Oregon, US

MARCONI	CHRISTIANO	Ingegneria biomedica	Biologia	University of Florida	Researcher, Lillian S. Wells Department of Neurosurgery, University of Florida
PERERA BEL	JÚLIA	Biologia	Biologia	Hospital del Mar Research Institute; Pompeu Fabra University	Head of Bioinformatics Unit, Hospital del Mar Research Institute; Associate lecturer in bioinformatics, Pompeu Fabra University, Barcelona, Spain
SLINGLUFF	CRAIG L.	Medicina e chirurgia	Immunologia; Oncologia	University of Virginia	Professor of Surgery, Division of Surgical Oncology, Breast and Melanoma Surgery; Director, Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia, US

Il provider, ai sensi dall' art. 47 del DPR n.445/2000, consapevole delle conseguenze previste dall'art. 76, dichiara:

- di aver fornito all'interessato l'informativa sul trattamento dei dati personali (art. 13 del Regolamento europeo 2016/679; artt. 68, 70, 76, 96 Accordo Stato-Regioni 2017 "La formazione continua nel settore salute"- Rep. Atti 14/CSR del 2.2.2017 - Par. 4.6, lett. j) Manuale Nazionale di Accreditamento per l'Erogazione di Eventi ECM);

- di aver informato l'interessato che il programma dell'evento ECM, di cui le suddette informazioni contribuiscono a formarne il contenuto minimo, verrà inserito nel catalogo degli eventi E.C.M. tenuto dall'ente accreditante;

Il Provider dichiara altresì che i CV dei Relatori, comprensivi della loro attività professionale e formativa, sono conservati in formato digitale e disponibili per la consultazione da parte della Commissione Nazionale.